Additional Description:
This provider manages ANDA, NDA, and IND submissions to China's NMPA end-to-end—covering gap analysis, compilation, submission, sample testing, CDE review tracking, and supplemental materials—alongside pre-submission gap analysis and strategy, pre-IND/NDA CDE meeting support, and filing and technical review of APIs, excipients, and packaging components. Its consultants bring over a decade of drug-registration experience, having secured 30+ imported drug registration certificates, 7+ Phase III approvals for an innovator, 5+ Phase I approvals for a domestic biosimilar, and 10+ clinical trial approvals for imported new drugs, supported by more than five former CDE experts.
Leave your rating & comment